News & Updates
Showing Multidisciplinary articles
Showing
Show Multimedia Only

Tenofovir alafenamide safe to use in breastfeeding mothers with CHB
16 Nov 2021
byStephen Padilla
The first human pharmacokinetic study of tenofovir alafenamide (TAF; commercially sold as Vemlidy) monotherapy in breastfeeding women with chronic hepatitis B (CHB) has found low concentrations of TAF and tenofovir in the breastmilk, with negligible exposure to infants.








